Philip A. van Damme
Founder at Stichting Sanammad
Philip A. van Damme active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Stichting Sanammad | Director/Board Member | 2008-12-31 | - |
| Founder | 2008-12-31 | - | |
| President | 2008-12-31 | - | |
| Sanammad Pharmaceuticals BV | Director/Board Member | 2013-12-31 | - |
| Founder | 2013-12-31 | - | |
| President | 2013-12-31 | - |
Career history of Philip A. van Damme
Former positions of Philip A. van Damme
| Companies | Position | Start | End |
|---|---|---|---|
| AXIM BIOTECHNOLOGIES, INC. | Director/Board Member | 2014-04-30 | 2020-05-05 |
| Chief Tech/Sci/R&D Officer | 2014-04-30 | 2020-05-05 | |
CanChew Biotechnologies LLC
 CanChew Biotechnologies LLC Pharmaceuticals: OtherHealth Technology CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets on the R&D and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g.: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms. | Director/Board Member | 2011-12-31 | - |
| Chief Tech/Sci/R&D Officer | 2013-07-29 | - |
Training of Philip A. van Damme
| University of Utrecht | Doctorate Degree |
Statistics
International
| Netherlands | 5 |
| United States | 2 |
Operational
| Director/Board Member | 4 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
| Miscellaneous | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| AXIM BIOTECHNOLOGIES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
CanChew Biotechnologies LLC
CanChew Biotechnologies LLC Pharmaceuticals: OtherHealth Technology CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets on the R&D and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g.: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms. | Health Technology |
| Stichting Sanammad | Miscellaneous |
| Sanammad Pharmaceuticals BV |
- Stock Market
- Insiders
- Philip A. van Damme
- Experience
